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The mandatory requirement to eliminate chlorofluorocarbons (CFCs) as propellants in pharmaceutical 
aerosols has provided the opportunity to enhance significantly the delivery of aerosol drugs to the respi- 
ratory tract. This randomized, parallel-group, double-blind, double-dummy, multicentre study was under- 
taken to assess whether beclomethasone dipropionate (BDP) in hydrofluoroalkane- 134a (HFA) provided 
equivalent control of moderately severe asthma to BDP in CFC but at approximately half the total daily 
dose, as might be expected from the improved lung deposition of the HFA-BDP extrafine aerosol. The 
novel study design included a lo-12 day run-in period to confirm that patients met established criteria of 
moderately severe asthma and were symptomatic on current therapy (inhaled B-agonist plus CFC-BDP 
400-800 pg day-i). This run-in period was followed by a short course of oral steroid therapy (prednisolone 
30 mg day-l for 7-13 days) to demonstrate steroid responsiveness [2 15% improvement in morning peak 
expiratory flow (PEF)] and to provide a within-study baseline of improved asthma control. A total of 233 
patients were randomized to treatment for 12 weeks with HFA-BDP 800 ,ug day-l (116 patients) or 
CFC-BDP 1500 pg day-l (117 patients). The mean change from oral steroid treatment in morning PEF 
with HFA-BDP was equivalent to that seen with CFC-BDP at all time intervals. Changes in other 
measures of pulmonary function, asthma symptom scores and B-agonist use were equivalent in the two 
treatment groups throughout the 12 week treatment period. The safety profile of HFA-BDP compared 
favourably with that of CFC-BDP with no unexpected adverse events reported. Fewer patients on 
HFA-BDP than on CFC-BDP had plasma cortisol levels below the normal reference range after 12 weeks 
of therapy (5.1% vs. 17.3%, respectively). In conclusion, HFA-BDP extrafine aerosol was found to pro- 
vide equivalent control of moderately severe asthma to CFC-BDP at approximately half the daily dose 
with a favourable safety profile, suggesting an improved therapeutic ratio. 
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Introduction 
The mandatory requirement to eliminate chlorofluoro- 
carbons (CFCs) as propellants in pharmaceutical 
Correspondence should be addressed to: P Stampone, 3M 
Pharmaceuticals, 3M Center, St. Paul, MN 55144-1000, 
U.S.A. 
This supplement was sponsored by 3M Pharmaceuticals. 
aerosols has provided the opportunity to enhance 
significantly the delivery of aerosol drugs to the 
respiratory tract. Hydrofluoroalkane- 134a (HFA) has 
been identified as a possible substitute for CFCs as a 
propellant in pressurized metered dose inhalers 
(MDIs). Unlike CFCs, HFA has no ozone-depleting 
potential (1). Pre-clinical studies have shown it to be 
well tolerated and to present no safety concerns (2), 
with HFA formulations of salbutamol and fluticasone 
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propionate appearing to be as effective and well toler- 
ated as CFC products at equivalent doses (3, 4). 
Beclomethasone dipropionate (BDP), an estab- 
lished corticosteroid widely used for the treatment of 
asthma, has also been reformulated using this new 
HFA propellant. In contrast to CFC-BDP products, 
this HFA formulation is a solution, rather than a sus- 
pension of BDP in propellant (5). This solution forms 
an extrafine aerosol of small droplets as the propellant 
evaporates. Existing CFC-BDP MDIs produce par- 
ticles approximately 3.5-4.0 pm in diameter while, in 
contrast, the new HFA-BDP extrafine aerosol has an 
average particle size of 1.1 pm (6). This results in more 
of the inhaled drug being delivered to the central and 
peripheral airways and a much smaller proportion 
being deposited in the oropharynx compared with 
existing CFC formulations (6). The improved pattern 
of drug distribution seen with the HFA-BDP extrafine 
aerosol is likely to be associated with a number of 
important therapeutic benefits. Firstly, since the extent 
of lung deposition is known to be a major determinant 
of the therapeutic efficacy of inhaled asthma therapy, 
with anti-inflammatory agents such as corticosteroids 
probably being more effective when deposited in the 
smaller airways (7, S), HFA-BDP should provide 
equivalent asthma control to existing CFC formula- 
tions, but at a significantly lower total daily dose. 
Secondly, the decreased oropharyngeal deposition 
seen with HFA-BDP should lead to a reduced poten- 
tial for local adverse effects. 
Previous studies have shown that low doses of 
100 pg day-r and 200 pg day-r HFA-BDP are effective 
in improving asthma control in patients with mild 
to moderate asthma (9). A recent study demonstrated 
that across the dose range 100-800 pg day-r higher 
doses of CFC-BDP (at least two times as high) 
were required to produce the same improvement in 
pulmonary function as HFA-BDP (10). In addition, 
400 pg day-r HFA-BDP was as effective as 
800 pg day-i CFCBDP for the treatment of moderate 
asthma (11). The present study was undertaken to 
determine whether HFA-BDP extrafine aerosol 
800 pg day-r provided equivalent control of pulmon- 
ary function to CFC-BDP 1500 Itg day-r in patients 
with moderately severe asthma who were inadequately 
controlled on current therapy (any inhaled steroid 
400-800 pg day-i). 
The study was designed to reflect current treatment 
guidelines and incorporated several features of critical 
interest. Firstly, patients were entered into a lo-12 day 
run-in period during which they continued to receive 
their previously prescribed asthma medications. This 
ensured that patients who were selected met estab- 
lished criteria of moderately severe asthma and were 
inadequately controlled on current therapy. Since 
these patients were clearly in need of additional treat- 
ment, they then received a short course of oral steroid 
therapy. Only patients showing an improvement in 
morning peak expiratory flow (PEF) of 15% or more 
were permitted to continue in the study, thus ensuring 
that all randomized patients were steroid responsive. 
This period of oral steroid treatment also served to 
provide a within-study baseline of improved asthma 
control against which the study medications could be 
assessed. Eligible patients were then randomly 
assigned to treatment with either HFA-BDP extrafine 
aerosol 800 Itg day-i or CFC-BDP 1500 p.g day-i. The 
dose of CFC-BDP used was consistent with current 
U.K. and international recommendations for the 
treatment of moderately severe asthma (12). The dose 
of HFA-BDP was selected on the prediction that 
equivalent asthma control to CFC-BDP could be 
achieved at a significantly lower total daily dose, 
because of the improved delivery characteristics of 
this new formulation. 
Methods 
STUDY DESIGN AND PATIENT 
POPULATION 
This was a 12 week randomized, parallel-group, 
double-blind, double-dummy multicentre study in 
adult patients (aged 18-65 years) with moderately 
severe asthma who were inadequately controlled on 
current therapy (a stable dose of inhaled steroid of 
400-800 ug day-i). Other screening criteria included 
concurrent use of a short-acting inhaled P-agonist for 
symptom relief and 15% or more reversibility in forced 
expiratory volume in 1 s (FEV,) in response to 
200400 I-18 salbutamol. 
All patients were entered into a lo-12 day run-in 
period, during which they continued to take their 
usual asthma medications as prescribed to confirm the 
presence of symptoms, lung function parameters and 
bronchodilator use consistent with the Global Initia- 
tive for Asthma classification of moderate to severe 
asthma (12). Only those patients who demonstrated a 
morning PEF of between 50% and 85% of the pre- 
dicted normal value, after withholding B-agonist ther- 
apy for at least 6 h, plus at least one of the following, 
were eligible to continue in the study: sleep distur- 
bance on at least one or more nights; asthma symp- 
toms on more than three days of wheezing, coughing, 
shortness of breath and/or chest tightness; average two 
puffs per day of an inhaled B-agonist for symptom 
relief 
Patients meeting these run-in criteria then received a 
short course of oral steroid treatment (prednisolone 
30 mg day-i for 7-13 days) to demonstrate that they 
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were steroid responsive (defined as an improvement in 
morning PEF of at least 15% over the last 3 days of 
the oral steroid treatment period) and to establish a 
within-study baseline of improved asthma control 
against which changes in study medications could be 
assessed. 
Patients were excluded from this study if they had 
any clinically significant abnormality or disease, 
known hypersensitivity to sympathomimetics, pred- 
nisolone or BDP, or an acute upper or lower respira- 
tory tract infection within the 4 weeks before the start 
of the trial or during the run-in period. Although use 
of an inhaled P-agonist bronchodilator to relieve 
symptoms of asthma as required was permitted 
throughout the study, patients were not allowed to 
receive any other therapy that might interfere with the 
evaluation of the study medications, for example, 
long-acting P-agonists, within the 4 weeks before 
screening or during the study period. The study was 
performed in accordance with the Declaration of 
Helsinki. Ethics committee approval was obtained at 
each study site before initiation, and all patients gave 
written informed consent. 
Eligible patients were then randomized in a double- 
blind, double-dummy manner to receive either 
HFA-BDP 800 pg day-i (QVARr”, 3M Pharma- 
ceuticals St. Paul, MN, U.S.A.; four inhalations of 
100 pg b. i d. plus three inhalations of placebo b. i. d.) or 
CFC-BDP 1500 pg day-1 (BecloforteTM, Allen & 
Hanburys Limited; three inhalations of 250 pg b.i.d. 
plus four inhalations of placebo b.i.d.). Treatment 
duration was 12 weeks. Patients were instructed to 
take their assigned study treatment in the morning 
and evening at about the same time each day. Patients 
were not permitted to take the following medications 
during the course of treatment: theophylline, sal- 
meterol, formoterol, anticholinergics, fluticasone pro- 
pionate, astemizole, monoamine oxidase inhibitors, 
tricyclic antidepressants or P-blockers. 
EFFICACY AND SAFETY ASSESSMENTS 
PEF, asthma symptoms and P-agonist use were 
assessed on a daily basis by the patients and recorded 
on a diary card. Morning and evening PEF measure- 
ments were taken using a mini-Wright peak flow meter, 
before inhaled P-agonist bronchodilator therapy or 
study medication was taken. Day-time symptoms of 
wheezing, shortness of breath, chest tightness and 
cough were rated on a scale of O-5 (0, not present; 5, 
so severe that the patient could not attend work or 
carry out normal daily activities). Night-time sleep 
disturbance was assessed on a scale of 04 (0, no 
asthma symptoms during the night; 4, asthma symp- 
toms so severe that the patient did not sleep at all). In 
addition, spirometry was performed at the screening 
visit, at the end of the run-in and oral steroid treatment 
periods, and at clinic visits every 3 weeks to determine 
FEV,. Compliance with the study medication was 
assessed by comparing the weights of all study inhaler 
canisters before dispatch with the weights of returned 
canisters and converting predicted and actual inhaler 
weights to number of administered doses. 
Adverse events were assessed throughout the study. 
Any patient reporting an oropharyngeal adverse event 
was examined by the investigator and had mouth or 
throat swabs taken for Candida culture if clinical signs 
were present. Plasma cortisol was measured at the end 
of the run-in period, following the course of oral 
steroids and after 12 weeks of treatment. Standard 
clinical chemistry assessments, physical examination 
and electrocardiography were performed pre- and 
post-study, and vital signs were monitored at all visits. 
STATISTICS 
An intention-to-treat analysis was performed. Last 
recorded values were carried forward to each succes- 
sive time point for patients who withdrew prematurely 
from the trial. For the primary efficacy variable 
(morning PEF), the mean change from oral steroid 
treatment was compared between treatment groups 
over weeks l-3,4-6, 7-9 and lo-12 using an analysis 
of variance (ANOVA) with treatment, centre and 
treatment-by-centre interaction terms. To confirm 
equivalence of the active treatments, the standard 
method for testing the equivalence, the two one-sided 
tests method was used; this method is equivalent to 
the use of a 90% confidence interval (CI) for assessing 
equivalence (13-15). The mean change from oral 
steroid treatment in morning and evening PEF in the 
patients who received HFA-BDP was considered to be 
equivalent to the mean for the patients receiving 
CFC-BDP if the 90% CI for the mean difference 
between the active treatments was within +25 1 mini 
using the two one-sided tests method (13, 14). For 
FEV,, a mean difference of within f0.2 1 was defined 
as equivalent. ANOVA for other secondary efficacy 
variables was performed using 90% CIs. Time to with- 
drawal because of asthma symptoms was compared 
among treatment groups using a Wilcoxon test and 
differences in the incidence of adverse events were 
compared using Fisher’s exact test. 
Results 
PATIENTS AND COMPLIANCE 
A total of 233 patients were randomized to therapy 
(116 to HFA-BDP and 117 CFCBDP). As shown 
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TABLE 1. Baseline patient characteristics 
HFA-BDP CFC-BDP 
800 pg day-l 1500 day-i* pg 
P values 
Number of patients 
Sex 
Female, n (%) 
Male, n (%) 
Age, mean (SD) years 
Inhaled steroid used 
CFC-BDP, n (%) 
Budesonide, IZ (%) 
Inhaled steroid dose, n (%) 
400 day-l pg 
800 day-l pg 
Others 
Morning PEF 
Actual, mean (SD) 1 min-1 
Percentage of predicted, mean (SD) 
FEV, 
Actual, mean (SD) 1 
Percentage of predicted, mean (SD) 
Percentage reversibility, mean (SD) 
116 117 
63 (54.3%) 68 (58.1%) 0.426 
53 (45.7%) 49 (41.9%) 
40.5 (13.34) 40.1 (14.12) 0.827 
105 (90.5%) 103 (88.0%) NA 
13 (11.2%)” 14 (12.0%) NA 
72 (62.1%) 72 (61.5%) NA 
20 (17.2%) 28 (23.9%) NA 
24 (20.7%) 14 (12.0%) NA 
365.3 (75.38) 364.1 (76.23) 0.902 
68.4 (9.74) 69.4 (10.77) 0.489 
2.08 (0.70) 2.16 (0.67) 0.413 
64.9 (15.62) 67.1 (13.87) 0.257 
29.0 (15.10) 30.2 (15.37) 0.572 
“Two patients received both CFC-BDP and budesonide. NA, not available. 
in Table 1, baseline patient demographics were 
comparable between the two treatment groups. The 
distribution of total daily dose of inhaled steroid used 
before study entry was also similar for the two treat- 
ment groups. Most patients (61.8%) were taking 
400 ng day-i inhaled steroid at study entry, usually 
CFC-BDP (89.3%). However, a substantial propor- 
tion (20.6%) were receiving a total daily dose of 
inhaled steroid of 800 ng day-l. 
A total of 207 patients (88.8%) completed the 12 
week course of inhaled steroid therapy. Twenty-six 
patients withdrew prematurely from the study; three 
patients in each treatment group (2.6%) with worsen- 
ing of asthma and five patients because of adverse 
events [two (1.7%) on HFA-BDP and three (2.6%) on 
CFC-BDP]. A further seven patients [Four (3.5%) on 
HFA-BDP and three (2.6%) on CFC-BDP] were 
withdrawn owing to violation of entry and protocol 
criteria, four patients [three (2.6%) on HFA-BDP and 
one (0.9%) on CFC-BDP] withdrew because of non- 
compliance. One patient (0.9%) on HFA-BDP with- 
drew because of intercurrent disease, while three other 
patients (2.7%) on CFC-BDP withdrew, one patient 
as a result of an inadequate response, a second patient 
withdrew their consent, and a third for personal 
reasons. 
Mean compliance with treatment 
HFA-BDP and 81.9% for CFC-BDP. 
EFFICACY 
was 76.3% for 
HFA-BDP 800 pg day-i provided equivalent control 
of morning PEF (within +25 1 mini) to CFC-BDP 
1500 ug day-i throughout the 12 week treatment 
period (Table 2; Fig. 1). There was a slight decline in 
morning PEF during the first 3 weeks following with- 
drawal of oral steroid therapy in both the HFA-BDP 
and the CFC-BDP treatment groups, after which 
morning PEF was maintained to an equivalent extent 
in both groups. The 90% CI was from -12.5 1 min-1 to 
11.9 1 min-1 for change in morning PEF at weeks 
10-12. 
All other efficacy variables supported the findings of 
this primary efficacy analysis. HFA-BDP and CFC- 
BDP were found to provide equivalent control of 
evening PEF at all time intervals tested, with the 
exception of weeks 4-6 when a trend in favour of 
HFA-BDP was observed (P=O.O71; 90% CI 4.52, 
26.15). As shown in Fig. 2, the improvement in FEV, 
seen following oral steroid therapy was maintained 
throughout the 12 week treatment period in both 
treatment groups. The mean change in FEV, following 
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TABLE 2. Mean change from oral steroid treatment for the primary efficacy variable, morn- 
ing PEF (1 min-1)” 
Study week HFA-BDP 
800 pg day-i 
CFC-BDP 
1500 ltg day-i 
Run in, mean (SE) 
Oral steroid therapy, mean (SE) 
Change at weeks 1-3, mean (SE) 
Change at weeks 446, mean (SE) 
Change at weeks 7-9, mean (SE) 
Change at weeks 10-12, mean (SE) 
349.1 (7.42) 344.9 (6.97) 
423.0 (8.46) 417.1 (7.95) 
-16.27 (3.75) -18.87 (3.52) 
-17.57 (480) -19.47 (4.51) 
-20.17 (5.37) -22.2t (5.05) 
-22.3t (5.37) -21.97 (5.05) 
*Based on an ANOVA with treatment, centre and treatment-by-centre interaction terms in 
the model. 
TP value for equivalence <O.OOl (equivalence defined as a 90% CI of the difference between 
the two treatments for change from oral steroid treatment in morning PEF within 
+25 1 min-1). 
FIG. 1. Adjusted mean morning PEF by week: 0, 
HFA-BDP 800 pg; 0, CFC-BDP 1500 pg. 
withdrawal of oral steroid therapy was found to be 
equivalent (within f0.2 1) for HFA-BDP and 
CFC-BDP at weeks 446 and 10-12. Otherwise, mean 
differences at weeks l-3 and 7-9 indicated a trend in 
favour of HFA-BDP (P=O.O74; 90% CI 0.016, 0.212 
and P=O.O66; 90% CI -0.024, 0.210, respectively). 
However, the 90% CI did not fall overall, indicating 
that HFA-BDP was no worse than CFC-BDP. 
disturbance due to asthma (Fig. 3). P-agonist use was 
also found to be comparable in the two treatment 
groups, changing little during the 12 weeks of therapy 
from the level of use during oral steroid treatment 
(Fig. 4). 
SAFETY AND TOLERABILITY 
Asthma symptom severity was also similar in the Treatment-related adverse events were reported by 
two treatment groups throughout the 12 week treat- 57 patients overall (24.5%), 30 in the HFA-BDP 
ment period, with both formulations providing equiv- treatment group (25.9%) and 27 in the CFC-BDP 
alent control of symptoms of wheezing, cough, treatment group (23.1%), with no clinically significant 
shortness of breath and chest tightness (Table 3). In differences in the incidence or type of adverse events 
addition, both HFA-BDP and CFC-BDP maintained documented between the two treatment groups. Five 
the improvement from the oral steroid treatment patients withdrew from the study because of adverse 
period in the percentage of nights without sleep events [two patients (1.7%) on HFA-BDP therapy and 
FIG. 2. Adjusted mean FEV, by week: q , HFA-BDP 
800 pg; 0, CFC-BDP 1500 pg. 
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Table 3. Adjusted mean change from oral steroid treatment in asthma symptom scores, 90% CIs of the differ- 
ence between HFA-BDP 800 pg and CFC-BDP 1500 ltg 
Mean difference (90% CI of difference) 
Study week Wheeze Cough Shortness of breath Chest tightness 
Run in 0.04 (-0.150, 0.230) -0.18 (-0.381,0.028) -0.12 (-0.331, 0~08s) -0.17 (-0.377, 0.032) 
Oral steroid -0.09 (-0.255, 0.072) -0.07 (-0.261, 0.114) -0.07 (-0.253, 0.123) -0.12 (-0.287, 0.054) 
treatment 
Weeks l-3 0.01 (-0~120,0~133) -0.09 (-0.220, 0.034) -0.08 (-0.214, 0.060) -0.02 (-0.158, 0.126) 
Weeks 4-6 -0.01 (-0.153, 0.141) -0.08 (-0.240, 0.087) -0.01 (-0~179,0~151) -0.04 (-0.212, 0.133) 
Weeks 7-9 0.06 (-0.101, 0,220) 0.03 (-0.146, 0.197) 0.05 (-0.126, 0.224) 0.07 (-0.116, 0.252) 
Weeks lo-12 0.05 (-0.119, 0.217) 0.04 (-0.147, 0.227) -0.05 (-0.235, 0.129) -0.00 (-0.190, 0.182) 
FIG. 3. Adjusted mean percentage of nights without 
sleep disturbance: q , HFA-BDP 800 pg; 0, CFC- 
BDP 1500 pg. 
three (2.6%) on CFC-BDP]. The most frequently 
reported adverse reactions were related to the route of 
drug administration in both treatment groups (Table 
4). Oropharyngeal candidiasis was diagnosed in only 
one patient during the course of the study in the 
CFC-BDP treatment group. 
Mean plasma cortisol levels were comparable 
between the two treatment groups at the end of the 
run-in period, after oral steroid treatment and at the 
end of the study. However, among patients with both 
a run-in and end-of-study plasma cortisol measure, 
more of those treated with CFC-BDP were found to 
have plasma cortisol levels below the normal reference 
range at the end of 12 weeks of inhaled steroid thera- 
py than in the HFA-BDP treatment group (Fig. 5). 
The difference was significant (P = O-024; Fisher’s 
exact test). No other clinically significant changes in 
FIG. 4. Adjusted mean daily B-agonist use; 0, 
HFA-BDP 800 pg; n , CFC-BDP 1500 pg. 
clinical chemistry or vital signs were apparent in either 
treatment group after inhaled steroid therapy. 
Discussion 
In this population of moderately severe asthmatic 
patients, HFA-BDP 800 pg day-i extrafine aerosol was 
found to provide equivalent asthma control to CFC- 
BDP 1500 pg day-1 over 12 weeks of treatment for all 
efficacy parameters evaluated. The mean change from 
oral steroid treatment in morning PEF with HFA- 
BDP was equivalent to that seen with CFC-BDP at all 
time intervals. There was a slight decline in morning 
PEF on discontinuation of oral steroid, after which 
both BDP formulations maintained the improvement 
in morning PEF to an equivalent extent. All other 
measures of pulmonary function, asthma symptom 
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TABLE 4. Incidence of adverse events possibly or probably related to treatment 
Adverse event HFA-BDP CFC-BDP 
800 pg day-i 1500 ug day-l 
Number (%) of patients reporting at least one 
treatment-related adverse event 
Inhalation route effects 
Cough 
Dysphonia 
Inhalation feel 
Inhalation taste 
Resistance mechanism effects 
Infection 
Application site effects 
Pharyngitis 
30 (25.9%) 27 (23.1%) 
3 (2.6%) - 
9 (7.8%) 4 (3.4%) 
10 (8.6%) 7 (6.0%) 
7 (6.0%) 7 (6.0%) 
3 (2.6%) 3 (2.6%) 
4 (3.4%) 2 (1.7%) 
HFA~BW30 pg 
n 
CFC,,,F$OO kg 
n 
FIG. 5. Patients with plasma cortisol levels below the 
normal range at week 12 (percentage of patients with 
both a run-in and an end-of-study cortisol measure). 
scores and P-agonist use were comparable in the two 
treatment groups throughout the 12 week treatment 
period. 
The safety profile of HFA-BDP was also found 
to compare favourably with that of CFC-BDP, with 
no unexpected adverse events reported. Reported 
adverse reactions tended to relate to the inhaled 
route of drug administration in both treatment 
groups. Only one case of oropharyngeal candidiasis 
was reported during the course of the study in the 
CFC-BDP treatment group. Interestingly, fewer 
patients on HFA-BDP than CFC-BDP had plasma 
cortisol levels below the normal reference range after 
12 weeks of therapy (4.35% vs. 14.43%, respectively), 
supporting an improved therapeutic ratio. This is 
significant because the increased lung deposition of 
HFA-BDP could potentially lead to greater systemic 
availability of BDP as a result of bypassing hepatic 
first-pass metabolism (16). However, coupled with 
results of other studies showing equivalent efficacy at 
a lower dose (1 l), and equivalent safety at the same 
dose (17), these findings would appear to suggest a 
more favourable safety profile for HFA-BDP com- 
pared with conventional CFC-BDP formulations at 
therapeutic dose. 
The finding that HFA-BDP provides equivalent 
asthma control to CFCBDP, but at approximately 
half the total daily dose, is not unexpected given the 
improved lung deposition of BDP seen with the HFA 
formulation (6). Available data indicate that HFA- 
BDP extrafine aerosol reverses the pattern of drug 
deposition seen with CFC-BDP, by delivering most of 
the inhaled dose to the airways and minimizing 
oropharyngeal deposition. Ex-actuator lung deposi- 
tion has been reported to be about 55% with HFA- 
BDP compared with no more than 10% for CFC-BDP 
(6, 18, 19), with oropharyngeal deposition of 30% and 
about 90%, respectively (6). Another recent study 
investigating lung deposition demonstrated lung deliv- 
ery of 7.6% with a CFC-BDP MD1 (20). 
The difficulty in establishing therapeutic equiva- 
lence, particularly for inhaled asthma medications, 
is well documented (21-28). The present study was 
designed to address some of the most common 
concerns and featured several points of critical inter- 
est. It is recognized that, although most asthmatic 
patients respond favourably to inhaled corticosteroids, 
there is considerable interindividual variation in 
response to therapy which could potentially interfere 
with the equivalence assessment (29-31). This study 
therefore incorporated a lo-12 day run-in period to 
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confirm that patients met established criteria of mod- 
erate to severe asthma and were symptomatic on 
current therapy (inhaled P-agonist plus CFC-BDP 
400-800 pg day-i). These patients were therefore 
clearly in need of additional treatment, so they 
received a short course of oral steroid therapy (pred- 
nisolone 30 mg day-l for 7-13 days) in accordance 
with current clinical practice (12, 32). This period of 
oral steroid therapy served to demonstrate steroid 
responsiveness (defined as 2 15% improvement in 
morning PEF) and also provided a within-study base- 
line of improved asthma control against which the 
equivalence of the study medications could be 
assessed. The need to establish a minimum level of 
treatment for adequate asthma control before ran- 
domization is also well recognized (21). 
The doses of inhaled steroids evaluated in this study 
were selected according to current U.K. and inter- 
national guidelines for the treatment of asthma of 
this severity (12, 32), while the dose of HFA-BDP 
(SOOug day-i) was selected on the assumption that 
equivalent asthma control to CFC-BDP could be 
achieved at a significantly lower total daily dose, 
because of the improved delivery characteristics 
of this new formulation (6). Although both BDP 
formulations were found to maintain the improvement 
in morning PEF to an equivalent extent over 12 weeks 
of treatment, the slight initial decline in morning 
PEF in both treatment groups following discontinua- 
tion of oral steroid treatment is noteworthy because it 
clearly demonstrates that these patients were not 
overtreated on the doses of inhaled steroid therapy 
evaluated. 
These patients were clearly inadequately controlled 
on current inhaled corticosteroid therapy, so it was 
not considered appropriate to include a placebo treat- 
ment arm. Other studies have clearly demonstrated 
the effectiveness of HFA-BDP compared with placebo 
(9, 11). No direct dose comparison was performed for 
the same reason (10). In retrospect, this may have been 
advantageous as the patients could have been at the 
top of their steroid dose-response curve on entering 
the study. However, it must be remembered that, 
in this case, all patients were symptomatic on their 
previous inhaled corticosteroid therapy. In a direct 
dose comparison, higher doses of CFC-BDP (at 
least two times as high) were required to produce the 
same improvement in pulmonary function as HFA- 
BDP (10). 
In conclusion, this study found that HFA-BDP 
extrafine aerosol provided equivalent control of 
moderately severe asthma as CFC-BDP, but at 
approximately half the total daily dose, probably 
because of the finer particle size and improved lung 
delivery characteristics of the new formulation. In 
addition, the safety profile of HFA-BDP was found to 
compare favourably with that of CFC-BDP and sug- 
gests that the HFA-BDP extrafine aerosol may have 
an improved therapeutic ratio. 
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